Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC

Overview

Altered fractionated radiotherapy and concomitant radio-chemotherapy have been shown to be two possibilities for improving efficacy of radiotherapy in locally advanced head and neck carcinomas. In this multicentric study, we tested the hypothesis that accelerated radiotherapy could be delivered concomitantly with conventional high doses of CDDP-5FU, aiming to improve both local control and on distant metastases as compared to very accelerated radiotherapy.

Full Title of Study: “A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

Patients with a palpable N2b-c or N3 HNSCC strictly unresectable were randomized to receive either accelerated RT-CT delivering to the primary tumor 62-64 Gy / 5 weeks in 31-32 fractions of 2 Gy BID or very accelerated RT delivering 62-64 Gy in 31-32 fractions of 2 Gy BID and 22-23 days. In the accelerated RT-CT arm, 3 cycles of CDDP 100 mg/m2 were delivered at day 1, 16, 32 and 2 cycles of 5 Fu 1000 mg/m2 day 1 to 5 and 31 to 35. One month after completion of the concomitant RT-CT, 2 additional cycles of CDDP-5FU were given in patients responding (> 50%) to the initial course of RT-CT. The end points were event free survival and survival.

Interventions

  • Procedure: Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)
  • Procedure: Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)
  • Drug: CDDP, 5 Fu

Clinical Trial Outcome Measures

Primary Measures

  • Event free survival (event = progressive disease or relapse or or death from any cause)

Secondary Measures

  • Survival
  • Toxicity

Participating in This Clinical Trial

Inclusion Criteria

  • palpable N2b-c or N3 (UICC 1997) squamous cell carcinoma of the head and neck (oropharynx, oral cavity, hypopharynx or larynx) – primary tumor and / or nodal extension strictly inoperable due to the extension of the disease – performance status of 0 to 2 (WHO scoring system) – renal/liver/cardiac functions and blood counts compatible with the use of CDDP and 5-FU – signed inform consent Exclusion Criteria:

  • distant metastasis – previous history of cancer – previous radiotherapy or chemotherapy

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gustave Roussy, Cancer Campus, Grand Paris
  • Overall Official(s)
    • Jean Bourhis, Principal Investigator, Gustave Roussy, Cancer Campus, Grand Paris
    • Michel Lapeyre, Principal Investigator, Centre Alexis Vautrin
    • Jacques Tortochaux, Principal Investigator, Centre Jean Perrin

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.